P279 Guselkumab was more effective than secukinumab in patients with plaque psoriasis and the subset of patients with self-reported PsA in the randomised, double-blind, head-to-head comparison study ECLIPSE over 1 year

Abstract Background Guselkumab (GUS, an antibody against IL-23) and secukinumab (SEC, an antibody against IL-17A) are both approved for the treatment of psoriasis (PsO). Up to 30% of patients with PsO may have psoriatic arthritis (PsA). The ECLIPSE study compared efficacy and safety of GUS vs SEC in...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Rheumatology (Oxford, England) England), 2020-04, Vol.59 (Supplement_2)
Hauptverfasser:	Merola, Joseph F, Li, Shu, Hsu, Ming-Chun, Karyekar, Chetan, Gorecki, Patricia C, Flavin, Susan, Randazzo, Bruce, Coates, Laura C
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!